Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Genmab A/S is one of the best cancer stocks on our list.

TheFly reported on January 8 that Deutsche Bank raised its price target for GMAB to DKK 2,400 from DKK 2,000 and reiterated a Buy rating, reflecting analysts’ optimism about the company’s late-stage oncology pipeline.

Separately, a day earlier, on January 7, Genmab A/S (NASDAQ:GMAB) partnered with AI research company Anthropic to enhance its R&D capabilities using agentic AI powered by Claude models. While keeping human control, the AI will automate complicated data processing and document creation. The partnership is a move toward a more scalable, effective, and digitally enabled R&D process, according to Tahamtan Ahmadi, EVP and Chief Medical Officer.

Genmab A/S (NASDAQ:GMAB) is a biotechnology company specializing in oncology, developing innovative antibody-based therapies for cancer treatment. Its late-stage pipeline includes promising programs like Rina‑S and Epkinly.

While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.